Relaxin and fibrosis: Emerging targets, challenges, and future directions

Anthony J. Kanai, Elisa M. Konieczko, Robert G. Bennett, Chrishan S. Samuel, Simon G. Royce

Research output: Contribution to journalReview ArticleResearchpeer-review

7 Citations (Scopus)

Abstract

The peptide hormone relaxin is well-known for its anti-fibrotic actions in several organs, particularly from numerous studies conducted in animals. Acting through its cognate G protein-coupled receptor, relaxin family peptide receptor 1 (RXFP1), serelaxin (recombinant human relaxin) has been shown to consistently inhibit the excessive extracellular matrix production (fibrosis) that results from the aberrant wound-healing response to tissue injury and/or chronic inflammation, and at multiple levels. Furthermore, it can reduce established scarring by promoting the degradation of aberrant extracellular matrix components. Following on from the review that describes the mechanisms and signaling pathways associated with the extracellular matrix remodeling effects of serelaxin (Ng et al., 2019), this review focuses on newly identified tissue targets of serelaxin therapy in fibrosis, and the limitations associated with (se)relaxin research.

Original languageEnglish
Pages (from-to)66-74
Number of pages9
JournalMolecular and Cellular Endocrinology
Volume487
DOIs
Publication statusPublished - 1 May 2019

Keywords

  • Challenges and future directions
  • Emerging targets
  • Extracellular matrix
  • Fibrosis
  • Relaxin
  • RXFP1

Cite this